GOOD THERAPEUTICS
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.
GOOD THERAPEUTICS
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2016-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.goodtherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
(253) 271-4341
Total Funding:
30.2 M USD
Similar Organizations
Antengene Corporation
Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Current Advisors List
Board_member
Board_member
Board_member
Current Employees Featured
John Mulligan Founder and CEO @ Good Therapeutics
Founder and CEO
Founder
Investors List
RiverVest
RiverVest investment in Series B - Good Therapeutics
Roche Venture Fund
Roche Venture Fund investment in Series B - Good Therapeutics
3×5 Partners
3×5 Partners investment in Series B - Good Therapeutics
Digitalis Ventures
Digitalis Ventures investment in Series B - Good Therapeutics
Roche Venture Fund
Roche Venture Fund investment in Series A - Good Therapeutics
Codon Capital
Codon Capital investment in Series A - Good Therapeutics
RiverVest
RiverVest investment in Series A - Good Therapeutics
Digitalis Ventures
Digitalis Ventures investment in Series A - Good Therapeutics
3x5 Partners
3x5 Partners investment in Series A - Good Therapeutics
RiverVest
RiverVest investment in Series A - Good Therapeutics
Official Site Inspections
http://www.goodtherapeutics.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago

More informations about "Good Therapeutics"
Good Therapeutics 2025 Company Profile: Valuation, Investors ...
503 Partners, American Century Investments, Codon Capital, Digitalis Ventures, and are 5 of 10 investors who have invested in Good Therapeutics. Who are Good Therapeutics’s …See details»
Good Therapeutics, Inc. | LinkedIn
Good Therapeutics, Inc. | 3,752 followers on LinkedIn. Systemic delivery, local activity | At Good Therapeutics we are developing protein-based drugs with regulated, context-dependent activity.See details»
Good Therapeutics - Company Profile - Tracxn
Good Therapeutics. has raised a total funding of $37.1M over 3 rounds. Its first funding round was on Nov 2018. What are the most recent funding rounds of Good Therapeutics? Its latest …See details»
Good Therapeutics Company Profile - Office Locations ... - Craft
Good Therapeutics is a biotechnology company developing protein drugs that sense biomarkers and respond with therapeutic activity. Its core technology is an algorithm for designing proteins …See details»
Good Therapeutics - Funding, Financials, Valuation & Investors
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. New. Resources. ... How much funding has this …See details»
Good Therapeutics - Products, Competitors, Financials, Employees ...
Good Therapeutics spinout Bonum banks $93 million in Series A. Nov 16, 2022. 16-11-2022 Bonum Therapeutics, a biopharma using allosteric regulation to create conditionally active and …See details»
Good Therapeutics Announces Acquisition of
Sep 7, 2022 Good Therapeutics Developing PD-1-regulated IL-2 Drugs Based on Innovative Conditionally Active Drug Technology September 07, 2022 07:00 AM Eastern Daylight TimeSee details»
Good Therapeutics - VentureRadar
Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. They are developing "context-dependent" protein drugs that sense biomarkers and respond with a …See details»
Good Therapeutics Company Information - Funding, Investors, …
Track over 71,000 companies. Discover Fast-growing Global startups. Seedtable uses technology and people to track over 71,000 companies to help you find the right ones to partner with.See details»
Good Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Explore Good Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 15 news, and 1 literature, Disease Domain:Neoplasms, Technology Platform:Recombinant …See details»
Good Therapeutics - Overview, News & Similar companies
Dec 30, 2021 Who is Good Therapeutics. Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. We are developing "context-dependent" protein drugs …See details»
Founder & CEO John Mulligan Shares Good Therapeutics
Jan 31, 2022 We founded Good Therapeutics to create a new kind of context-dependent drug that is active only when and where it is needed. When we started, many natural proteins were …See details»
Good Therapeutics lands $8M to develop protein drugs that
Dec 30, 2021 Good Therapeutics is developing an IL-2-based agent that is active when bound to immune T cells that recognize tumors. The therapeutic binds a target on such cells, PD-1, then …See details»
CASE STUDY: GOOD THERAPEUTICS - RiverVest
Aug 3, 2023 Good Therapeutics, founded in 2016 by molecular biologist John Mulligan, Ph.D., was acquired by Roche in 2022 for $250 million upfront plus potential milestone payments. …See details»
Good Therapeutics - Contacts, Employees, Board Members
Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. ... Log In. Log In. Experience the new …See details»
Good Therapeutics - Raised $37.1M Funding from 6 investors
Feb 28, 2025 Good Therapeutics has raised a total funding of $37.1M over 3 rounds from 6 investors. Investors include Roche, RiverVest Venture Partners and 4 others. Their latest …See details»
Good Therapeutics - VentureRadar
Similar Companies: CStone China Privately Held CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and …See details»
Good Therapeutics raises $11M to develop ‘context ... - GeekWire
May 21, 2020 Seattle biotech startup Good Therapeutics raised another $11 million to create "context dependent" protein drugs that act only when needed. The 4-year-old. Toggle search …See details»
Roche to acquire Good Therapeutics' lead drug program for
Sep 7, 2022 Good Therapeutics previously raised $600,000 in Seed funding, $22 million in a Series A round in 2020 and $10 million in a recent Series B round. Roche Venture Fund is an …See details»
ATA ACTION ACQUIRES DIGITAL THERAPEUTICS ALLIANCE, …
5 days ago WASHINGTON, DC, MARCH 31, 2025 – ATA Action, the advocacy arm of the American Telemedicine Association (ATA), today announced it has acquired the Digital …See details»